Clinical Trials Browser

Phase 2 × Somatostatinoma × regorafenib × Clear all

NCT02259725 2021-12-15

Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors

Phase 2 Completed

3 enrolled 7 charts

Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell